\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\ and\\ laboratory\\:\\ \ \(0\)\
\-\ normal\\ physical\\ exam\\ except\\ for\\ bilateral\\ decreased\\ range\\ of\\ motion\\ of\\ the\\ hips\\ and\\ atalgic\\ gait\\ secondary\\ to\\ hip\\ pain\\.\\ \\ laboratory\\ studies\\ showed\\ mild\\ macrocytic\\ anemia\\ and\\ leukopenia\\.\ \(0\)\
\-\ treatment\\ and\\ follow\\-up\\:\\ the\\ patient\\ is\\ currently\\ receiving\\ chemotherapy\\ via\\ the\\ pog\\ 9906\\ protocol\\,\\ currently\\ a\\ phase\\ iii\\ randomized\\ study\\ of\\ multidrug\\ antimetabolite\\ therapy\\ in\\ children\\ recently\\ diagnosed\\ with\\ acute\\ lymphoblastic\\ leukemia\\ designated\\ as\\ high\\ risk\\.\\ \\ the\\ protocol\\ specifies\\ a\\ number\\ of\\ short\\ bursts\\ of\\ steroids\\ over\\ the\\ course\\ of\\ the\\ 130\\-week\\ regimen\\,\\ which\\ has\\ been\\ halted\\ in\\ this\\ patient\\.\ \(0\)\
\-\ imaging\\ findings\\:\\ anteroposterior\\ \\(ap\\)\\ radiograph\\ of\\ the\\ hips\\ at\\ presentation\\ was\\ normal\\ and\\ showed\\ normal\\ mineralization\\ with\\ no\\ evidence\\ of\\ subluxation\\,\\ dislocation\\,\\ fractures\\,\\ or\\ osteoblastic\\/osteolytic\\ changes\\.\\ \\ magnetic\\ resonance\\ \\(mr\\)\\ imaging\\ of\\ both\\ the\\ right\\ and\\ left\\ hips\\ demonstrated\\ subchondral\\ low\\ signal\\ intensity\\ of\\ the\\ femoral\\ head\\ on\\ coronal\\ t1\\ imaging\\,\\ best\\ seen\\ on\\ the\\ left\\,\\ that\\ becomes\\ high\\ signal\\ intensity\\ on\\ a\\ coronal\\ stir\\ \\(fat\\ suppressed\\)\\ image\\.\\ \\ there\\ was\\ also\\ increased\\ signal\\ intensity\\ of\\ the\\ femoral\\ neck\\,\\ particularly\\ the\\ lateral\\ margin\\,\\ on\\ stir\\ imaging\\.\\ \\ a\\ subsequent\\ ap\\ hip\\ radiograph\\ 2\\ months\\ after\\ presentation\\ shows\\ new\\ subchondral\\ fracture\\ lucencies\\ in\\ the\\ right\\ and\\ left\\ femoral\\ heads\\ and\\ mild\\ flattening\\ of\\ the\\ left\\ superior\\ head\\ along\\ with\\ bilateral\\ preserved\\ joint\\ space\\.\\ \\ a\\ year\\ after\\ presentation\\,\\ an\\ ap\\ hip\\ radiograph\\ showed\\ an\\ increase\\ in\\ collapse\\ of\\ the\\ left\\ femoral\\ head\\ and\\ bilateral\\ early\\ degenerative\\ change\\ of\\ the\\ hips\\.\ \(0\)\
\-\ avascular\\ necrosis\\ of\\ hip\ \(0\)\
\-\ differential\\ diagnosis\\ for\\ these\\ findings\\ in\\ this\\ case\\:\ \(0\)\
\-\ avascular\\ necrosis\\ secondary\\ to\\ steroid\\ therapy\ \(0\)\
\-\ history\\ \\(can\\ include\\ gestational\\ age\\,\\ or\\ age\\ in\\ days\\,\\ weeks\\,\\ months\\)\\:\\ 18\\ year\\ old\\ male\\ with\\ a\\ 1\\ year\\ history\\ of\\ pre\\ b\\-cell\\ acute\\ lymphocytic\\ leukemia\\ currently\\ on\\ chemotherapy\\ protocol\\ that\\ includes\\ treatment\\ with\\ vincristine\\,\\ methotrexate\\,\\ prednisone\\/dexamethasone\\ surges\\,\\ and\\ 6\\-mp\\.\\ patient\\ complains\\ of\\ recent\\ onset\\ of\\ bilateral\\ hip\\ pain\\.\ \(0\)\
\-\ discussion\\ \\(include\\ references\\)\\:\\ avascular\\ necrosis\\ of\\ the\\ hip\\ may\\ be\\ a\\ difficult\\ diagnosis\\ to\\ make\\ when\\ a\\ patient\\ first\\ presents\\ with\\ hip\\ pain\\ or\\ mild\\ gait\\ abnormalities\\.\\ \\ initial\\ radiographs\\ of\\ the\\ hips\\ may\\ no\\ show\\ no\\ changes\\,\\ as\\ in\\ this\\ case\\.\\ \\ therefore\\,\\ clinical\\ suspicion\\ should\\ be\\ high\\ for\\ this\\ disorder\\ in\\ a\\ patient\\ whose\\ history\\ suggests\\ the\\ diagnosis\\.\\ \\ avascular\\ necrosis\\ is\\ caused\\ by\\ a\\ number\\ of\\ etiologies\\ including\\ femoral\\ neck\\ fracture\\,\\ alcohol\\ use\\,\\ sickle\\ cell\\ disease\\,\\ systemic\\ lupus\\ erythematosus\\,\\ radiation\\ treatment\\,\\ and\\ prolonged\\ corticosteroid\\ administration\\,\\ as\\ in\\ this\\ patient\\.\\ \\ steroids\\ have\\ been\\ implicated\\ in\\ about\\ 20\\ to\\ 35\\ percent\\ of\\ cases\\.\\ \\ the\\ occurrence\\ also\\ appears\\ to\\ be\\ directly\\ related\\ to\\ the\\ dosage\\ level\\ and\\ duration\\ of\\ the\\ medication\\.\\ \\ in\\ decreasing\\ order\\ of\\ frequency\\,\\ the\\ most\\ common\\ locations\\ of\\ steroid\\-induced\\ avasular\\ osteonecrosis\\ are\\ the\\ femoral\\ head\\,\\ humeral\\ head\\,\\ the\\ distal\\ end\\ of\\ the\\ femur\\,\\ and\\ the\\ proximal\\ part\\ of\\ the\\ tibia\\.\\ \\ \ \(0\)\
\-\ the\\ pathogenesis\\ of\\ steroid\\-induced\\ osteonecrosis\\ is\\ unclear\\.\\ \\ however\\ several\\ mechanisms\\ have\\ been\\ proposed\\ and\\ include\\ both\\ mechanical\\ and\\ vascular\\ etiologies\\.\\ \\ osteoporosis\\ resulting\\ in\\ microfractures\\ and\\ later\\ bone\\ collapse\\ is\\ one\\ mechanical\\ theory\\.\\ \\ vascular\\ compromise\\ due\\ to\\ hyperviscosity\\,\\ vasculitis\\,\\ fat\\ embolization\\,\\ and\\ compression\\ from\\ marrow\\ accumulation\\ of\\ relatively\\ inelastic\\ fat\\ cells\\ are\\ also\\ other\\ possible\\ causes\\.\ \(0\)\
\-\ \\ \\ \ \(31891\)\
\-\ the\\ most\\ common\\ presenting\\ symptom\\ of\\ avascular\\ necrosis\\ is\\ pain\\.\\ \\ groin\\ pain\\ and\\ less\\ commonly\\ thigh\\ and\\ buttock\\ pain\\ are\\ seen\\ in\\ patients\\ with\\ femoral\\ head\\ involvement\\.\\ \\ patients\\ may\\ also\\ complain\\ of\\ pain\\ upon\\ weight\\ bearing\\.\\ \\ thirty\\ to\\ fifty\\ percent\\ have\\ bilateral\\ involvement\\.\\ \\ physical\\ exam\\ usually\\ is\\ nonspecific\\ and\\ may\\ demonstrate\\ limited\\ range\\ of\\ motion\\ particularly\\ in\\ abduction\\ and\\ internal\\ rotation\\.\ \(0\)\
\-\ radiographic\\ evaluation\\ of\\ a\\ patient\\ with\\ suspected\\ osteonecrosis\\ includes\\ an\\ ap\\ and\\ frog\\-leg\\ radiograph\\ of\\ both\\ hips\\.\\ \\ as\\ mentioned\\ above\\,\\ the\\ initial\\ radiographs\\ may\\ not\\ show\\ any\\ evidence\\ of\\ disease\\.\\ \\ subsequently\\,\\ radiographic\\ findings\\ show\\ sclerosis\\,\\ indistinctive\\ trabecular\\ pattern\\,\\ and\\ patchy\\ osteoporosis\\.\\ \\ progressive\\ radiograph\\ findings\\ include\\ a\\ crescentic\\ subchondral\\ line\\ indicative\\ of\\ subchondral\\ collapse\\,\\ segmental\\ flattening\\ of\\ the\\ femoral\\ head\\,\\ and\\ ultimately\\ joint\\ space\\ narrowing\\,\\ acetabular\\ degenerative\\ changes\\,\\ and\\ collapse\\ of\\ the\\ femoral\\ head\\.\ \(0\)\
\-\ mr\\ imaging\\ is\\ the\\ most\\ sensitive\\ test\\ for\\ detecting\\ avascular\\ necrosis\\.\\ \\ as\\ with\\ this\\ patient\\,\\ mr\\ imaging\\ showed\\ evidence\\ of\\ osteonecrosis\\ prior\\ to\\ the\\ radiographs\\.\\ \\ t1\\-weighted\\ images\\ typically\\ show\\ a\\ line\\ of\\ low\\ signal\\ intensity\\,\\ which\\ corresponds\\ to\\ the\\ presence\\ of\\ granulation\\ tissue\\ and\\ sclerotic\\ bone\\.\\ \\ t2\\-weighted\\ images\\ typically\\ demonstrate\\ a\\ double\\ line\\ sign\\,\\ which\\ consists\\ of\\ a\\ narrower\\ line\\ of\\ low\\ signal\\ intensity\\ that\\ corresponds\\ to\\ bone\\ sclerosis\\ and\\ an\\ inner\\ zone\\ of\\ high\\ signal\\ intensity\\ that\\ corresponds\\ to\\ granulation\\ tissue\\.\\ \\ \\ \ \(0\)\
\-\ references\ \(24\)\
\-\ laporte\\ et\\ al\\.\\ \\ \\‚\\Ä\\úmultifocal\\ osteonecrosis\\.\\‚\\Ä\\ù\\ \\ journal\\ of\\ rheumatology\\.\\ \\ 25\\(10\\)\\,\\ oct\\ 1998\\,\\ pp\\ 1968\\-74\\.\\ \ \(0\)\
\-\ donald\\ resnick\\.\\ \\ diagnosis\\ of\\ bone\\ and\\ joint\\ disorders\\.\\ \\ philadelphia\\:\\ w\\.b\\.\\ saunders\\ co\\.\\ 2002\\.\\ pp\\.\\ 3599\\-3637\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ hips\\:\\ 0\\.035020850046739466\ \(0\)\
\-\ femoral\\:\\ 0\\.03394313474454088\ \(0\)\
\-\ avascular\\:\\ 0\\.03274694589183193\ \(0\)\
\-\ hip\\:\\ 0\\.027641654993944557\ \(0\)\
\-\ osteonecrosis\\:\\ 0\\.024409143213350738\ \(0\)\
\-\ necrosis\\:\\ 0\\.02347865925831581\ \(0\)\
\-\ head\\:\\ 0\\.02249281958769277\ \(0\)\
\-\ intensity\\:\\ 0\\.021498867817025296\ \(0\)\
\-\ subchondral\\:\\ 0\\.02081106767368987\ \(0\)\
\-\ collapse\\:\\ 0\\.0202917269952491\ \(0\)\
\-\ corresponds\\:\\ 0\\.018961331533573166\ \(0\)\
\-\ steroid\\-induced\\:\\ 0\\.018845408917416595\ \(0\)\
\-\ line\\:\\ 0\\.01629797455177458\ \(0\)\
\-\ protocol\\:\\ 0\\.015995396933145212\ \(0\)\
\-\ radiograph\\:\\ 0\\.01578856527796614\ \(0\)\
\-\ signal\\:\\ 0\\.01568265195085461\ \(0\)\
\-\ granulation\\:\\ 0\\.014688194371643846\ \(0\)\
\-\ ap\\:\\ 0\\.014501897770962587\ \(0\)\
\-\ imaging\\:\\ 0\\.013935548662103963\ \(0\)\
\-\ \\,\\:\\ 0\\.01381814719577801\ \(0\)\
\-\ showed\\:\\ 0\\.01300140727574801\ \(0\)\
\-\ stir\\:\\ 0\\.012894250315417669\ \(0\)\
\-\ pp\\:\\ 0\\.012894250315417669\ \(0\)\
\-\ show\\:\\ 0\\.012172417329427499\ \(0\)\
\-\ bilateral\\:\\ 0\\.01202910515843645\ \(0\)\
\-\ osteoporosis\\:\\ 0\\.012013763954153394\ \(0\)\
\-\ currently\\:\\ 0\\.011784824112570964\ \(0\)\
\-\ include\\:\\ 0\\.011123682079026852\ \(0\)\
\-\ etiologies\\:\\ 0\\.010992995313366075\ \(0\)\
\-\ mechanical\\:\\ 0\\.01095399967922134\ \(0\)\
\-\ may\\:\\ 0\\.010871974297552923\ \(0\)\
\-\ high\\:\\ 0\\.010851721861145316\ \(0\)\
\-\ flattening\\:\\ 0\\.010804258330874306\ \(0\)\
\-\ percent\\:\\ 0\\.010804258330874306\ \(0\)\
\-\ presentation\\:\\ 0\\.010243853716326272\ \(0\)\
\-\ particularly\\:\\ 0\\.010229232428543492\ \(0\)\
\-\ atalgic\\:\\ 0\\.010226819517362526\ \(0\)\
\-\ macrocytic\\:\\ 0\\.010226819517362526\ \(0\)\
\-\ pog\\:\\ 0\\.010226819517362526\ \(0\)\
\-\ 9906\\:\\ 0\\.010226819517362526\ \(0\)\
\-\ multidrug\\:\\ 0\\.010226819517362526\ \(0\)\
\-\ antimetabolite\\:\\ 0\\.010226819517362526\ \(0\)\
\-\ specifies\\:\\ 0\\.010226819517362526\ \(0\)\
\-\ 130\\-week\\:\\ 0\\.010226819517362526\ \(0\)\
\-\ halted\\:\\ 0\\.010226819517362526\ \(0\)\
\-\ osteoblastic\\/osteolytic\\:\\ 0\\.010226819517362526\ \(0\)\
\-\ prednisone\\/dexamethasone\\:\\ 0\\.010226819517362526\ \(0\)\
\-\ avasular\\:\\ 0\\.010226819517362526\ \(0\)\
\-\ microfractures\\:\\ 0\\.010226819517362526\ \(0\)\
\-\ hyperviscosity\\:\\ 0\\.010226819517362526\ \(0\)\
\-\ inelastic\\:\\ 0\\.010226819517362526\ \(0\)\
\-\ indistinctive\\:\\ 0\\.010226819517362526\ \(0\)\
\-\ laporte\\:\\ 0\\.010226819517362526\ \(0\)\
\-\ osteonecrosis\\.\\:\\ 0\\.010226819517362526\ \(0\)\
\-\ 1968\\-74\\.\\:\\ 0\\.010226819517362526\ \(0\)\
\-\ 3599\\-3637\\:\\ 0\\.010226819517362526\ \(0\)\
\-\ leukemia\\:\\ 0\\.010173321636016667\ \(0\)\
\-\ number\\:\\ 0\\.009887799379039344\ \(0\)\
\-\ bone\\:\\ 0\\.009853525203990115\ \(0\)\
\-\ joint\\:\\ 0\\.009617503207803066\ \(0\)\
\-\ mr\\:\\ 0\\.009449650134384341\ \(0\)\
\-\ leukopenia\\:\\ 0\\.009422704458708298\ \(0\)\
\-\ designated\\:\\ 0\\.009422704458708298\ \(0\)\
\-\ bursts\\:\\ 0\\.009422704458708298\ \(0\)\
\-\ surges\\:\\ 0\\.009422704458708298\ \(0\)\
\-\ 6\\-mp\\:\\ 0\\.009422704458708298\ \(0\)\
\-\ radiographs\\:\\ 0\\.009418576013464498\ \(0\)\
\-\ steroids\\:\\ 0\\.009326514799001756\ \(0\)\
\-\ gait\\:\\ 0\\.009232567324860835\ \(0\)\
\-\ \\:\\:\\ 0\\.009178565791107488\ \(0\)\
\-\ diagnosis\\:\\ 0\\.009105426128911461\ \(0\)\
\-\ fat\\:\\ 0\\.00904493847870638\ \(0\)\
\-\ degenerative\\:\\ 0\\.008988111372058455\ \(0\)\
\-\ narrower\\:\\ 0\\.00861858940005407\ \(0\)\
\-\ changes\\:\\ 0\\.008523368826804155\ \(0\)\
\-\ pain\\:\\ 0\\.008474776302453762\ \(0\)\
\-\ findings\\:\\ 0\\.00844007858835248\ \(0\)\
\-\ low\\:\\ 0\\.008269726402087237\ \(0\)\
\-\ coronal\\:\\ 0\\.008255273902410015\ \(0\)\
\-\ references\\:\\ 0\\.008243220963019982\ \(0\)\
\-\ lymphoblastic\\:\\ 0\\.008148212244476151\ \(0\)\
\-\ been\\:\\ 0\\.00809093349001389\ \(0\)\
\-\ includes\\:\\ 0\\.007992761939301242\ \(0\)\
\-\ range\\:\\ 0\\.007981995397406804\ \(0\)\
\-\ motion\\:\\ 0\\.007971278585675264\ \(0\)\
\-\ dosage\\:\\ 0\\.007969383149548937\ \(0\)\
\-\ fifty\\:\\ 0\\.007969383149548937\ \(0\)\
\-\ patient\\:\\ 0\\.00794980910363237\ \(0\)\
\-\ mild\\:\\ 0\\.007831508540363585\ \(0\)\
\-\ also\\:\\ 0\\.007817260295453139\ \(0\)\
\-\ frog\\-leg\\:\\ 0\\.007814474341399839\ \(0\)\
\-\ evidence\\:\\ 0\\.007797363979235073\ \(0\)\
\-\ donald\\:\\ 0\\.007677835088898234\ \(0\)\
\-\ co\\:\\ 0\\.007677835088898234\ \(0\)\
\-\ both\\:\\ 0\\.007594663540670956\ \(0\)\
\-\ randomized\\:\\ 0\\.0075556071124970444\ \(0\)\
\-\ implicated\\:\\ 0\\.0075556071124970444\ \(0\)\
\-\ radiographic\\:\\ 0\\.007525207405542305\ \(0\)\
\-\ as\\:\\ 0\\.007497549338132991\ \(0\)\
\-\ thirty\\:\\ 0\\.007344097185821923\ \(0\)\
\-\ laboratory\\:\\ 0\\.007306477345369062\ \(0\)\
\-\ physical\\:\\ 0\\.007296422051906861\ \(0\)\
\-\ involvement\\:\\ 0\\.00726667901769795\ \(0\)\
\-\ theory\\:\\ 0\\.007251240216363064\ \(0\)\
\-\ rheumatology\\:\\ 0\\.007251240216363064\ \(0\)\
\-\ crescentic\\:\\ 0\\.007165268090894709\ \(0\)\
\-\ 2002\\.\\:\\ 0\\.007165268090894709\ \(0\)\
\-\ sclerosis\\:\\ 0\\.007121381052033283\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.007106602749746786\ \(0\)\
\-\ whose\\:\\ 0\\.0070852299569191275\ \(0\)\
\-\ w\\.b\\:\\ 0\\.0070852299569191275\ \(0\)\
\-\ typically\\:\\ 0\\.006998667678668149\ \(0\)\
\-\ resnick\\:\\ 0\\.006940029095023529\ \(0\)\
\-\ a\\:\\ 0\\.006901388662736681\ \(0\)\
\-\ most\\:\\ 0\\.006866015574459661\ \(0\)\
\-\ that\\:\\ 0\\.006849098508393612\ \(0\)\
\-\ in\\:\\ 0\\.006844038540560985\ \(0\)\
\-\ pathogenesis\\:\\ 0\\.006810997035730925\ \(0\)\
\-\ erythematosus\\:\\ 0\\.006751492053842815\ \(0\)\
\-\ mechanisms\\:\\ 0\\.006751492053842815\ \(0\)\
\-\ suppressed\\:\\ 0\\.006694890935316792\ \(0\)\
\-\ vincristine\\:\\ 0\\.006694890935316792\ \(0\)\
\-\ this\\:\\ 0\\.006690050208683061\ \(0\)\
\-\ buttock\\:\\ 0\\.006640923399777473\ \(0\)\
\-\ anteroposterior\\:\\ 0\\.006589355229741704\ \(0\)\
\-\ oct\\:\\ 0\\.006589355229741704\ \(0\)\
\-\ initial\\:\\ 0\\.0065697961561004825\ \(0\)\
\-\ space\\:\\ 0\\.006558136907370382\ \(0\)\
\-\ pre\\:\\ 0\\.006539982127167694\ \(0\)\
\-\ proposed\\:\\ 0\\.006539982127167694\ \(0\)\
\-\ detecting\\:\\ 0\\.006539982127167694\ \(0\)\
\-\ exam\\:\\ 0\\.0065332967747663735\ \(0\)\
\-\ vascular\\:\\ 0\\.006500703637874005\ \(0\)\
\-\ occurrence\\:\\ 0\\.00649262482494002\ \(0\)\
\-\ acetabular\\:\\ 0\\.00649262482494002\ \(0\)\
\-\ have\\:\\ 0\\.00644003971588779\ \(0\)\
\-\ trabecular\\:\\ 0\\.006403342874666089\ \(0\)\
\-\ corticosteroid\\:\\ 0\\.00636115303224048\ \(0\)\
\-\ abduction\\:\\ 0\\.00636115303224048\ \(0\)\
\-\ lymphocytic\\:\\ 0\\.006320443844524389\ \(0\)\
\-\ methotrexate\\:\\ 0\\.006320443844524389\ \(0\)\
\-\ decreasing\\:\\ 0\\.006320443844524389\ \(0\)\
\-\ unclear\\:\\ 0\\.006320443844524389\ \(0\)\
\-\ 1998\\:\\ 0\\.006320443844524389\ \(0\)\
\-\ of\\:\\ 0\\.006217140181795206\ \(0\)\
\-\ regimen\\:\\ 0\\.006206244224091381\ \(0\)\
\-\ complain\\:\\ 0\\.006206244224091381\ \(0\)\
\-\ saunders\\:\\ 0\\.006206244224091381\ \(0\)\
\-\ b\\-cell\\:\\ 0\\.006170546244199556\ \(0\)\
\-\ mineralization\\:\\ 0\\.006037819618703333\ \(0\)\
\-\ age\\:\\ 0\\.006034594722840618\ \(0\)\
\-\ treatment\\:\\ 0\\.006019548583297751\ \(0\)\
\-\ heads\\:\\ 0\\.006006881977076697\ \(0\)\
\-\ compromise\\:\\ 0\\.006006881977076697\ \(0\)\
\-\ lucencies\\:\\ 0\\.005947376995188586\ \(0\)\
\-\ to\\:\\ 0\\.005945263690621618\ \(0\)\
\-\ mentioned\\:\\ 0\\.005918731272925974\ \(0\)\
\-\ preserved\\:\\ 0\\.005863478315861874\ \(0\)\
\-\ and\\:\\ 0\\.0058471602790047756\ \(0\)\
\-\ lupus\\:\\ 0\\.005836808341123244\ \(0\)\
\-\ neck\\:\\ 0\\.005821909830669333\ \(0\)\
\-\ resonance\\:\\ 0\\.005810737742686982\ \(0\)\
\-\ locations\\:\\ 0\\.005785240171087475\ \(0\)\
\-\ ultimately\\:\\ 0\\.005785240171087475\ \(0\)\
\-\ the\\:\\ 0\\.005773752029385764\ \(0\)\
\-\ groin\\:\\ 0\\.005760290977095637\ \(0\)\
\-\ receiving\\:\\ 0\\.005735867068513465\ \(0\)\
\-\ bearing\\:\\ 0\\.005735867068513465\ \(0\)\
\-\ magnetic\\:\\ 0\\.0056885097662857905\ \(0\)\
\-\ indicative\\:\\ 0\\.005665536880791383\ \(0\)\
\-\ symptom\\:\\ 0\\.0056209124250746825\ \(0\)\
\-\ journal\\:\\ 0\\.0056209124250746825\ \(0\)\
\-\ philadelphia\\:\\ 0\\.0055570379735862515\ \(0\)\
\-\ which\\:\\ 0\\.00555154728738706\ \(0\)\
\-\ left\\:\\ 0\\.005545854230121315\ \(0\)\
\-\ secondary\\:\\ 0\\.005542992961737372\ \(0\)\
\-\ subluxation\\:\\ 0\\.0055163287858701615\ \(0\)\
\-\ an\\:\\ 0\\.005483363639372296\ \(0\)\
\-\ sickle\\:\\ 0\\.00547699983961067\ \(0\)\
\-\ directly\\:\\ 0\\.005438960601996991\ \(0\)\
\-\ t1\\-weighted\\:\\ 0\\.005438960601996991\ \(0\)\
\-\ consists\\:\\ 0\\.005438960601996991\ \(0\)\
\-\ thigh\\:\\ 0\\.005420398721084647\ \(0\)\
\-\ months\\:\\ 0\\.005415177017842383\ \(0\)\
\-\ sensitive\\:\\ 0\\.005384142870151811\ \(0\)\
\-\ inner\\:\\ 0\\.005331798977715071\ \(0\)\
\-\ multifocal\\:\\ 0\\.005331798977715071\ \(0\)\
\-\ patchy\\:\\ 0\\.005314863015509558\ \(0\)\
\-\ therapy\\:\\ 0\\.0053007907105350645\ \(0\)\
\-\ make\\:\\ 0\\.005298170744683456\ \(0\)\
\-\ gestational\\:\\ 0\\.005281715251653344\ \(0\)\
\-\ accumulation\\:\\ 0\\.005281715251653344\ \(0\)\
\-\ prolonged\\:\\ 0\\.005265489912935548\ \(0\)\
\-\ zone\\:\\ 0\\.005265489912935548\ \(0\)\
\-\ duration\\:\\ 0\\.0052494883791393354\ \(0\)\
\-\ humeral\\:\\ 0\\.0052494883791393354\ \(0\)\
\-\ steroid\\:\\ 0\\.005233704560049104\ \(0\)\
\-\ frequency\\:\\ 0\\.005233704560049104\ \(0\)\
\-\ fracture\\:\\ 0\\.0052275506502848694\ \(0\)\
\-\ segmental\\:\\ 0\\.005202766918422468\ \(0\)\
\-\ common\\:\\ 0\\.005188555016140133\ \(0\)\
\-\ becomes\\:\\ 0\\.005187602090618114\ \(0\)\
\-\ suspicion\\:\\ 0\\.0051432619365343575\ \(0\)\
\-\ patients\\:\\ 0\\.005131263571614909\ \(0\)\
\-\ nonspecific\\:\\ 0\\.005100554311101972\ \(0\)\
\-\ vasculitis\\:\\ 0\\.005072931748812275\ \(0\)\
\-\ end\\:\\ 0\\.005032693282469016\ \(0\)\
\-\ \\(\\:\\ 0\\.0050280398578458965\ \(0\)\
\-\ except\\:\\ 0\\.005019584749691831\ \(0\)\
\-\ t2\\-weighted\\:\\ 0\\.005019584749691831\ \(0\)\
\-\ alcohol\\:\\ 0\\.004993803848549476\ \(0\)\
\-\ medication\\:\\ 0\\.004993803848549476\ \(0\)\
\-\ order\\:\\ 0\\.004968583446419074\ \(0\)\
\-\ \\)\\:\\ 0\\.004966619666681938\ \(0\)\
\-\ suggests\\:\\ 0\\.004956175918441409\ \(0\)\
\-\ anemia\\:\\ 0\\.004931752009859237\ \(0\)\
\-\ acute\\:\\ 0\\.004895311668460546\ \(0\)\
\-\ part\\:\\ 0\\.004805904396177021\ \(0\)\
\-\ double\\:\\ 0\\.004795112757357631\ \(0\)\
\-\ rotation\\:\\ 0\\.004763327404471188\ \(0\)\
\-\ systemic\\:\\ 0\\.0047426109109677\ \(0\)\
\-\ disorders\\:\\ 0\\.0047426109109677\ \(0\)\
\-\ tissue\\:\\ 0\\.0046993531054584535\ \(0\)\
\-\ therefore\\:\\ 0\\.00468259272720994\ \(0\)\
\-\ short\\:\\ 0\\.004672884780956441\ \(0\)\
\-\ phase\\:\\ 0\\.004663257399500878\ \(0\)\
\-\ dislocation\\:\\ 0\\.004663257399500878\ \(0\)\
\-\ margin\\:\\ 0\\.004663257399500878\ \(0\)\
\-\ normal\\:\\ 0\\.0046622243199504676\ \(0\)\
\-\ iii\\:\\ 0\\.0046537092566510925\ \(0\)\
\-\ discussion\\:\\ 0\\.004644239058693828\ \(0\)\
\-\ recently\\:\\ 0\\.004625527478728767\ \(0\)\
\-\ embolization\\:\\ 0\\.0046162836624304175\ \(0\)\
\-\ complains\\:\\ 0\\.004607112920542816\ \(0\)\
\-\ be\\:\\ 0\\.004586160290060078\ \(0\)\
\-\ is\\:\\ 0\\.004566166413797076\ \(0\)\
\-\ demonstrate\\:\\ 0\\.004562533970610303\ \(0\)\
\-\ 35\\:\\ 0\\.004562316126891099\ \(0\)\
\-\ tibia\\:\\ 0\\.004553560667917337\ \(0\)\
\-\ subsequently\\:\\ 0\\.004494055686029228\ \(0\)\
\-\ disorder\\:\\ 0\\.004453346498313136\ \(0\)\
\-\ sclerotic\\:\\ 0\\.004437454567503204\ \(0\)\
\-\ marrow\\:\\ 0\\.004361105126007181\ \(0\)\
\-\ resulting\\:\\ 0\\.004353739432644468\ \(0\)\
\-\ difficult\\:\\ 0\\.004339146877880129\ \(0\)\
\-\ case\\:\\ 0\\.004337597292035431\ \(0\)\
\-\ 18\\:\\ 0\\.004303448897988303\ \(0\)\
\-\ children\\:\\ 0\\.004282545759354105\ \(0\)\
\-\ femur\\:\\ 0\\.004282545759354105\ \(0\)\
\-\ suspected\\:\\ 0\\.004268816690158046\ \(0\)\
\-\ via\\:\\ 0\\.004255248198553416\ \(0\)\
\-\ relatively\\:\\ 0\\.004241836571638015\ \(0\)\
\-\ test\\:\\ 0\\.004235188457126431\ \(0\)\
\-\ al\\:\\ 0\\.004202507625378524\ \(0\)\
\-\ on\\:\\ 0\\.004198903784022204\ \(0\)\
\-\ limited\\:\\ 0\\.0041833321010731755\ \(0\)\
\-\ best\\:\\ 0\\.00417072227249208\ \(0\)\
\-\ increase\\:\\ 0\\.004158248036092704\ \(0\)\
\-\ caused\\:\\ 0\\.004158248036092704\ \(0\)\
\-\ administration\\:\\ 0\\.004115615156500197\ \(0\)\
\-\ history\\:\\ 0\\.004107475189235789\ \(0\)\
\-\ after\\:\\ 0\\.004102090957329936\ \(0\)\
\-\ related\\:\\ 0\\.0040919389713131825\ \(0\)\
\-\ et\\:\\ 0\\.004057306763482925\ \(0\)\
\-\ are\\:\\ 0\\.004054085403235272\ \(0\)\
\-\ upon\\:\\ 0\\.004051633926714721\ \(0\)\
\-\ presenting\\:\\ 0\\.004040370801277411\ \(0\)\
\-\ 25\\:\\ 0\\.004007223037421198\ \(0\)\
\-\ cells\\:\\ 0\\.003974996164907189\ \(0\)\
\-\ narrowing\\:\\ 0\\.003974996164907189\ \(0\)\
\-\ use\\:\\ 0\\.0039181428248762215\ \(0\)\
\-\ progressive\\:\\ 0\\.0039181428248762215\ \(0\)\
\-\ seen\\:\\ 0\\.003917929501317146\ \(0\)\
\-\ change\\:\\ 0\\.0038639460446355488\ \(0\)\
\-\ subsequent\\:\\ 0\\.003859142340846649\ \(0\)\
\-\ causes\\:\\ 0\\.003859142340846649\ \(0\)\
\-\ about\\:\\ 0\\.003821412420074538\ \(0\)\
\-\ images\\:\\ 0\\.0038033965010425847\ \(0\)\
\-\ pattern\\:\\ 0\\.0037893762634237564\ \(0\)\
\-\ fractures\\:\\ 0\\.003753815078863429\ \(0\)\
\-\ course\\:\\ 0\\.0037407557348673333\ \(0\)\
\-\ commonly\\:\\ 0\\.0037407557348673333\ \(0\)\
\-\ compression\\:\\ 0\\.0037108437660091954\ \(0\)\
\-\ studies\\:\\ 0\\.0037024372596045937\ \(0\)\
\-\ \\‚\\Ä\\ú\\:\\ 0\\.0037024372596045937\ \(0\)\
\-\ appears\\:\\ 0\\.0036899406273749984\ \(0\)\
\-\ \\‚\\Ä\\ù\\:\\ 0\\.0036816837042092628\ \(0\)\
\-\ diagnosed\\:\\ 0\\.00364523800092228\ \(0\)\
\-\ abnormalities\\:\\ 0\\.0036412582618308774\ \(0\)\
\-\ above\\:\\ 0\\.003633339508848975\ \(0\)\
\-\ early\\:\\ 0\\.0036254744427406467\ \(0\)\
\-\ presence\\:\\ 0\\.003598359186145161\ \(0\)\
\-\ risk\\:\\ 0\\.003590726969094068\ \(0\)\
\-\ including\\:\\ 0\\.0035793719733096564\ \(0\)\
\-\ later\\:\\ 0\\.0035793719733096564\ \(0\)\
\-\ 20\\:\\ 0\\.003564402826168232\ \(0\)\
\-\ weight\\:\\ 0\\.003553301374873393\ \(0\)\
\-\ or\\:\\ 0\\.0034855780126347127\ \(0\)\
\-\ new\\:\\ 0\\.0034545104139217615\ \(0\)\
\-\ sign\\:\\ 0\\.003434392693461799\ \(0\)\
\-\ for\\:\\ 0\\.003383332476300302\ \(0\)\
\-\ less\\:\\ 0\\.0033572389841330422\ \(0\)\
\-\ 10\\:\\ 0\\.0033417914481982717\ \(0\)\
\-\ possible\\:\\ 0\\.0033387264720232852\ \(0\)\
\-\ recent\\:\\ 0\\.0033326207063106694\ \(0\)\
\-\ year\\:\\ 0\\.003327512538072789\ \(0\)\
\-\ first\\:\\ 0\\.003326546908104237\ \(0\)\
\-\ internal\\:\\ 0\\.003323521892550779\ \(0\)\
\-\ cases\\:\\ 0\\.003302564807402706\ \(0\)\
\-\ along\\:\\ 0\\.0032761645903231044\ \(0\)\
\-\ study\\:\\ 0\\.0032617533142226905\ \(0\)\
\-\ radiation\\:\\ 0\\.003253191704828696\ \(0\)\
\-\ disease\\:\\ 0\\.0032406903508485014\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.003225100918145872\ \(0\)\
\-\ several\\:\\ 0\\.003186882640049173\ \(0\)\
\-\ superior\\:\\ 0\\.0031655959362577625\ \(0\)\
\-\ should\\:\\ 0\\.0031603347353698374\ \(0\)\
\-\ differential\\:\\ 0\\.0031472851848641874\ \(0\)\
\-\ t1\\:\\ 0\\.003142106190515364\ \(0\)\
\-\ onset\\:\\ 0\\.003129258962790197\ \(0\)\
\-\ any\\:\\ 0\\.0031216183678332873\ \(0\)\
\-\ image\\:\\ 0\\.003096507153477495\ \(0\)\
\-\ clinical\\:\\ 0\\.0030502433875475685\ \(0\)\
\-\ days\\:\\ 0\\.0030383692530997417\ \(0\)\
\-\ usually\\:\\ 0\\.003010357603093688\ \(0\)\
\-\ no\\:\\ 0\\.002994585211266132\ \(0\)\
\-\ proximal\\:\\ 0\\.0029762681922355164\ \(0\)\
\-\ decreased\\:\\ 0\\.0029475132282187465\ \(0\)\
\-\ demonstrated\\:\\ 0\\.0029088398868410293\ \(0\)\
\-\ evaluation\\:\\ 0\\.0028796273733489646\ \(0\)\
\-\ level\\:\\ 0\\.0028571798464581575\ \(0\)\
\-\ when\\:\\ 0\\.002839131366143858\ \(0\)\
\-\ weeks\\:\\ 0\\.002813547281787875\ \(0\)\
\-\ however\\:\\ 0\\.0027602877675140026\ \(0\)\
\-\ shows\\:\\ 0\\.00272549153100798\ \(0\)\
\-\ distal\\:\\ 0\\.0026952187806798455\ \(0\)\
\-\ one\\:\\ 0\\.0026864633217060837\ \(0\)\
\-\ cell\\:\\ 0\\.0026777734473103086\ \(0\)\
\-\ due\\:\\ 0\\.00264533312407522\ \(0\)\
\-\ these\\:\\ 0\\.002579866231969652\ \(0\)\
\-\ prior\\:\\ 0\\.0025453744457103983\ \(0\)\
\-\ over\\:\\ 0\\.002523947320347984\ \(0\)\
\-\ increased\\:\\ 0\\.002425156359396352\ \(0\)\
\-\ 1\\:\\ 0\\.002358847294616829\ \(0\)\
\-\ was\\:\\ 0\\.002292987290518995\ \(0\)\
\-\ other\\:\\ 0\\.0022849635135759262\ \(0\)\
\-\ can\\:\\ 0\\.002248517810288944\ \(0\)\
\-\ lateral\\:\\ 0\\.002142306317429873\ \(0\)\
\-\ 2\\:\\ 0\\.0021346919913115383\ \(0\)\
\-\ right\\:\\ 0\\.002091952921369876\ \(0\)\
\-\ presents\\:\\ 0\\.0020251093915405172\ \(0\)\
\-\ has\\:\\ 0\\.00186160089384487\ \(0\)\
\-\ male\\:\\ 0\\.0017925818304959085\ \(0\)\
\-\ \\.\\:\\ 0\\.0017296757727245284\ \(0\)\
\-\ by\\:\\ 0\\.0016506623007481146\ \(0\)\
\-\ there\\:\\ 0\\.0014753080701449984\ \(0\)\
\-\ from\\:\\ 0\\.0014691829618958378\ \(0\)\
\-\ not\\:\\ 0\\.00143250425956141\ \(0\)\
\-\ at\\:\\ 0\\.0013431127063011983\ \(0\)\
\-\ with\\:\\ 0\\.0012216213280846955\ \(0\)\
\-\ old\\:\\ 0\\.0010150053327868383\ \(0\)\
